A statement released today by Bernstein Research about Bayer (ETR:BAYN) ups the target price to 120.00EUR
- Updated: January 11, 2017
Yesterday Bayer (ETR:BAYN) traded 0.00% even at 101.05EUR. The company’s 50-day moving average is 0.04EUR and its 200-day moving average is 0.03EUR. The last stock close price is up -69.79% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.04% over the date range. Volume of trade was down over the average, with 0 shares of BAYN changing hands under the typical 211
In a report released on Wednesday January 11, 2017 Bernstein Research increased the price target of Bayer (ETR:BAYN) to 120.00EUR indicating a possible upside of 0.19%.
Previously on 01/10/2017, Commerzbank AG reported about Bayer (ETR:BAYN) raised the target price from 0.00EUR to 118.00EUR. At the time, this indicated a possible upside of 0.16%.
With a total market value of 0 EUR, Bayer has with a one year low of 0.01EUR and a one year high of 0.04EUR .
Brief Synopsis About Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.